Recent Investment Analysts’ Ratings Updates for Nektar Therapeutics (NKTR)

A number of research firms have changed their ratings and price targets for Nektar Therapeutics (NASDAQ: NKTR):

• 9/9/2026 – Nektar Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $178.00 price target on the stock.
• 8/28/2026 – Nektar Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 8/24/2026 – Nektar Therapeutics was upgraded by TD Cowen to “strong-buy”.
• 8/21/2026 – Nektar Therapeutics is now covered by JPMorgan Chase & Co.. They set a “neutral” rating and a $65.00 price target on the stock.
• 7/22/2026 – Nektar Therapeutics is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $153.00 price target on the stock.

Insider Transactions at Nektar Therapeutics

In related news, CEO Howard W. Robin sold 418 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $71.98, for a total value of $30,087.64. Following the completion of the transaction, the chief executive officer owned 54,627 shares of the company’s stock, valued at approximately $3,932,051.46. This trade represents a 0.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jonathan Zalevsky sold 5,681 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $70.00, for a total value of $397,670.00. Following the completion of the transaction, the insider owned 9,756 shares in the company, valued at $682,920. This represents a 36.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 21,823 shares of company stock valued at $1,380,558 over the last ninety days. Insiders own 2.50% of the company’s stock.

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.